Alphyn Biologics, Inc.
Tuesday, February 27, 2024
Plymouth
Dermatology
Alphyn is developing first-in-class Multi-Target Therapeutics® for severe and prevalent skin diseases based on its AB-101 platform, which has multiple bioactive compounds and, therefore, multiple mechanisms of action to support a robust pipeline of dermatologic therapeutics that have potential safety, efficacy, and regulatory marketing authorization advantages. We are initially targeting the $118 Billion atopic dermatitis (AD) market. After only 3½ years, Alphyn’s first drug candidate, topical zabalafin (formerly AB-101a) completed two Phase 2a clinical trials in AD with market-leading results, providing a faster path to regulatory approval and huge commercial opportunity, with clinical results pointing to a potential “drug of choice” for this vast 800 million patient population. Our second candidate is for epidermolysis bullosa (EB), a collection of rare and life-threatening skin diseases.
State
Maryland
Country
United States
Website
http://www.alphynbiologics.com
CEO/Top Company Official
CEO Neal Koller
Lead Product in Development
Our lead product candidate zabalafin (formerly AB-101a) has successfully completed two Phase 2a trials for atopic dermatitis, and we are preparing for Phase 2b. Clinical trial results show superiority to current commercialized therapeutics and clinical-stage pipeline candidates.
Development Phase of Primary Product
Phase II
Number Of Unlicensed Products
Two
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
)
)
){kind=logo}